The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

HEPARIN SODIUM

2,000 USP Units per 1,000 mL

(2 USP Units/mL)

In 0.9% Sodium Chloride Injection SINGLE DOSE CONTAINER

Case NDC	**Unit NDC**	**Lot Number**	**Expiration Date**	**Configuration/Count**
0409-7620-59	0409-7620-49	5935283	1 Dec 2023	12 units per case

Hospira Inc., a Pfizer company, is recalling the above-referenced lot of **HEPARIN SODIUM**. Pfizer initiated this recall due to confirmed reports of leaking bags. Pfizer completed a Health Hazard Assessment which concluded that the use of the impacted product has a low probability of occurrence of moderate adverse events such as blood stream infections, wound infection, diarrhea, acute gastroenteritis, or abdominal pain. The potential risk to the patient arising from this issue is considered to be medium.

The recall of the above-referenced lot of **HEPARIN SODIUM** is being conducted to the **Hospital/Institution Level**. Tthe affected lot was distributed between **August 2022 through November 2022.**